AvroBio Inc

+0.96 (+6.18%)
Products, Other Pre-Announcement

Avrobio Inc Says Exclusive Worldwide License Agreement And Collaborative Research Funding Agreement With University Of Manchester

Published: 10/05/2020 11:16 GMT
Avrobio Inc (AVRO) - Avrobio Inc - Announced Exclusive, Worldwide License Agreement & Collaborative Research Funding Agreement With University of Manchester.
Avrobio Inc - License Agreement for an Investigational Lentiviral Gene Therapy for Mucopolysaccharidosis Type Ii (mps Ii), Or Hunter Syndrome.
Avrobio Inc - Investigator-sponsored Phase 1/2 Clinical Trial for Hunter Syndrome is Expected to Enter Clinic in H2 of 2021.
Avrobio Inc - Under Agreement, Co to Pay University of Manchester Upfront Cash Payment, Additional Payments on Development, Regulatory Milestones.
Avrobio Inc - Co Will Also Pay University of Manchester a Mid-single Digit Percentage Royalty on Annual Net Sales of Licensed Products.
Avrobio Inc - Under Collaborative Research Funding Agreement, Co Will Cover Budgeted Phase 1/2 Clinical Trial Costs.